ICD-10 Coding for Fibrocystic Breast(N60.01, N60.19, N60.19B)
Learn about ICD-10 coding for fibrocystic breast, including N60.19 for diffuse cystic mastopathy. Ensure accurate documentation with imaging and pathology confirmation.
Complete code families applicable to Fibrocystic Breast
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| N60.19 | Diffuse cystic mastopathy | Use for generalized fibrocystic changes with multiple cysts, confirmed by imaging and pathology. |
|
| N60.3 | Fibrosclerosis | Use when documentation specifies dominant stromal fibrosis. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutFibrocystic Breast
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Fibrocystic Breast.
Using outdated terminology like 'fibrocystic disease'.
Impact
Clinical: May lead to miscommunication among healthcare providers., Regulatory: Non-compliance with current coding standards., Financial: Potential for denied claims due to lack of specificity.
Mitigation
Use current terminology such as 'diffuse cystic mastopathy'.
Using unspecified codes for fibrocystic changes
Impact
Reimbursement: May lead to lower reimbursement rates., Compliance: Non-compliance with specificity requirements., Data Quality: Decreases accuracy of clinical data.
Mitigation
Ensure imaging and pathology confirm specific diagnosis to use N60.19 or N60.3.
Laterality Documentation
Impact
Failure to document laterality can lead to audit issues.
Mitigation
Ensure laterality is documented in all clinical notes and imaging reports.